骨质疏松症药物治疗的必由之路:长程序贯治疗  

Long-term sequential treatment strategies for osteoporosis

作　　者：李梅 章振林[2] 夏维波 LI Mei;ZHANG Zhen-lin;XIA Wei-bo(Department of Endocrinology,Key Laboratory of Endocrinology of National Health Commission,Peking Union Medical College Hospital,Chinese Academy of Medical Science&Peking Union Medical College,Beijing 100730,China;Department of Osteoporosis and Bone Disease,Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,Shanghai 200233,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院内分泌科国家卫生健康委员会内分泌重点实验室,北京100730 [2]上海交通大学附属第六人民医院骨质疏松和骨病专科,上海200233

出　　处：《中华骨质疏松和骨矿盐疾病杂志》2021年第5期441-446,共6页Chinese Journal Of Osteoporosis And Bone Mineral Research

基　　金：国家自然科学基金面上项目(81873668,82070908);北京市自然科学基金(7202153);国家重点研发计划(2018YFA0800801)。

摘　　要：随着社会人口老龄化,我国骨质疏松症患病率急剧攀升。有效防控骨质疏松症,减少骨质疏松性骨折发生率,对于减轻疾病对国民健康和社会经济的危害具有重要意义。目前骨质疏松症治疗药物主要包括骨吸收抑制剂、骨形成促进剂和双重作用药物,上述药物长程序贯治疗能够持续增加骨密度、降低骨折风险,是骨质疏松症药物治疗的必然趋势,但基于骨折风险的科学序贯治疗方案仍需深入探索。With the aging of the population,the prevalence of osteoporosis has rapidly risen in China.Effective prevention and treatment of osteoporosis to decrease the incidence of bone fractures are of great significance.At present,the drugs for treatment of osteoporosis mainly include antiresorptic,anabolic and dual acting agents.The long-term sequential treatment can continuously increase bone mineral density and reduce the bone fracture risk,which is the inevitable trend of treatment of osteoporosis.However,the appropriate sequential treatment protocol based on fracture risk still needs to be further explored.

关 键 词：骨质疏松症 骨吸收抑制剂 骨形成促进剂 序贯治疗 

分 类 号：R681[医药卫生—骨科学]